Sign In

Kevin Eisenfrats

Founder & CEO at Contraline

Kevin Eisenfrats is the CEO and co-founder of Contraline, a biotechnology company at the forefront of reproductive health innovation. Under his leadership, Contraline has developed ADAM, the world's first long-lasting reversible male contraceptive, securing over $25M in funding and transitioning the company to a clinical-stage entity. Before Contraline, Kevin's work spanned drug development in immuno-oncology and non-hormonal contraception, leading to the filing of 50+ patents in contraceptive drugs, medical devices, and biomaterials. He holds a degree in Nanomedicine Engineering from the University of Virginia, recognized by Forbes in 2017 as one of the 30 Under 30 in Healthcare. Besides, he engages as an angel investor and startup advisor with a keen interest in biotech, deep tech, and women's health startups.

Highlights

Apr 26 · Business Wire
Contraline Announces Acceptance of Abstracts to be Presented at ... - Business Wire
Contraline Announces Acceptance of Abstracts to be Presented at ... - Business Wire
Apr 26 · Yahoo Finance
Contraline Announces Acceptance of Abstracts to be Presented at 2023 American Urology Association and European Association of Urology Annual Meetings - Yahoo Finance
Contraline Announces Acceptance of Abstracts to be Presented at 2023 American Urology Association an
Kevin Eisenfrats
Add to my network

Location

Charlottesville, Virginia, United States